Once a decision has been made to prescribe OPSYNVI®,

Begin Treatment With OPSYNVI® Today

Follow these 3 steps to get your patients with PAH started on OPSYNVI® (macitentan/tadalafil):

1

Complete

the Enrollment and Prescription Form

2

Verify

your patient’s insurance

3

Contact

a specialty pharmacy

1

Complete the Enrollment and Prescription Form

After prescribing OPSYNVI® (macitentan/
tadalafil), there are 2 forms your healthcare team needs to fill out before moving forward.

Patient Authorization Form

Patient Authorization Form

A release form that allows providers, insurers, and Johnson & Johnson to share medical information about your patients.

Enrollment and Prescription Form

Enrollment and Prescription Form

A form required to get your patient started on OPSYNVI®. It also includes information on access and voucher programs.

PATHwatch Portal

Sign up or log in to the J&J withMe PAH Provider Portal at PATHwatch.net, where you can complete and submit the Enrollment and Prescription Form, receive real-time alerts on pending actions, and view shipment status for J&J's oral PAH medicines.

2

Verify your patient’s insurance

Your patient’s insurance company may need more information before approving OPSYNVI®. This may include prior authorizations, exceptions, and appeals. Visit www.jnjwithme.com or reach out to a Care Coordinator for assistance.

Care Coordinators can look into a patient’s insurance coverage, support
the prior authorization process, and more.

Arrow Icon
What does current coverage look like?

60 percent coverage
  • 60% of OPSYNVI® coverage does not have a step requirement1*

Arrow Icon
What might that mean for your patients?

  • Some insurers may require starting on a PDE5i or ERA before covering OPSYNVI®
    • Review local coverage and step therapy requirements with your Therapy Access Manager (TAM), using the most current plan data
3

Contact a specialty pharmacy

OPSYNVI® is only available through specialty pharmacies, which deliver it to patients by mail. When your patients are enrolled, they are connected to a specialty pharmacy based on their health insurance or an indicated preference.

The following are specialty pharmacies that can provide OPSYNVI® to your patients:

Accredo
866-344-4874
CVS Specialty
877-242-2738
CenterWell
800-486-2668
Kaiser Permanente
877-404-5777

Average time to approval for OPSYNVI® (19.5 days) is comparable to OPSUMIT® (17.8 days)

Cumulative Time to Approval for OPSUMIT® and OPSYNVI® Utilizing J&J withMe2†
Approval comparison chart
Approval comparison chart

J&J withMe offers support through Therapy Access Managers who can educate on payer-specific requirements and reduce delays, and Care Coordinators who can assist with benefits verification and cost support options.

The patient support and resources provided by J&J withMe are not intended to provide medical advice, replace a treatment plan from the patient's doctor or nurse, provide case management services, or serve as a reason to prescribe a J&J medicine.

Review patient cases


and see if OPSYNVI® is right for your patients with PAH

*

Based on coverage data from MMIT as of May 2025.

Of the approvals.

ERA=endothelin receptor antagonist; PAH=pulmonary arterial hypertension; PDE5i=phosphodiesterase type 5 inhibitor.

References: 1. Data on file. Johnson & Johnson and its affiliates US, Inc. MMIT, May 2025. May 9, 2025. 2.  Data on file. Johnson & Johnson and its affiliates US, Inc. April 1, 2024-March 31, 2025, Accessed on December 5, 2025.